Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (191-200 of 333) with videos related to

Pageof 34
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
p53 overexpression as a prognostic factor for advanced stage bladder cancerM A Kuczyk, C Bokemeyer, J Serth, et al.
Arzneimittel-Forschung|March 1, 1993
Pen-based remote data entry system. A pilot clinical trialI Beinlich, C Bokemeyer, U Räth, et al.
British Journal of Cancer|December 1, 1996
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activityC Bokemeyer, L M Fels, T Dunn, et al.
British Journal of Cancer|March 1, 2002
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PETC Bokemeyer, C Kollmannsberger, K Oechsle, et al.
Leukemia|June 3, 2005
Antiangiogenic treatment with endostatin inhibits progression of AML in vivoG Schuch, L Oliveira-Ferrer, S Loges, et al.
BJU International|April 12, 2002
The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experienceM Kuczyk, T Münch, S Machtens, et al.
Oncology Letters|September 12, 2012
Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patientsJ Köllermann, H Albrecht, T Schlomm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancerC Bokemeyer, J Beyer, B Metzner, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 15, 1996
[Cytokine therapy and the endocrine system: is it necessary to monitor more than the thyroid gland?]F Schuppert, E Müller-Kunert, W Stöcker, et al.
World Journal of Urology|June 21, 2002
Recent strategies for the use of paclitaxel in the treatment of urological malignanciesC Bokemeyer, J T Hartmann, M A Kuczyk, et al.
Pageof 34

Showing results (191-200 of 333) with videos related to

Sort By:
Pageof 34
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
p53 overexpression as a prognostic factor for advanced stage bladder cancerM A Kuczyk, C Bokemeyer, J Serth, et al.
Arzneimittel-Forschung|March 1, 1993
Pen-based remote data entry system. A pilot clinical trialI Beinlich, C Bokemeyer, U Räth, et al.
British Journal of Cancer|December 1, 1996
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activityC Bokemeyer, L M Fels, T Dunn, et al.
British Journal of Cancer|March 1, 2002
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PETC Bokemeyer, C Kollmannsberger, K Oechsle, et al.
Leukemia|June 3, 2005
Antiangiogenic treatment with endostatin inhibits progression of AML in vivoG Schuch, L Oliveira-Ferrer, S Loges, et al.
BJU International|April 12, 2002
The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experienceM Kuczyk, T Münch, S Machtens, et al.
Oncology Letters|September 12, 2012
Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patientsJ Köllermann, H Albrecht, T Schlomm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancerC Bokemeyer, J Beyer, B Metzner, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 15, 1996
[Cytokine therapy and the endocrine system: is it necessary to monitor more than the thyroid gland?]F Schuppert, E Müller-Kunert, W Stöcker, et al.
World Journal of Urology|June 21, 2002
Recent strategies for the use of paclitaxel in the treatment of urological malignanciesC Bokemeyer, J T Hartmann, M A Kuczyk, et al.
Pageof 34